Medidata Platform Selected for Leukemia Trial

Article

Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML).

Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML). Medidata is also incorporating its EDC, management and reporting solution, Medidata Rave, and its medical coding solution, Medidata Coder, to this trial.

Read the full release here

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.